Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Date and time:  Tuesday 21 November 2023, 13:30 hours (1.30 pm UK GMT)

Location: L1 Main Meeting Room, Richard Doll Building, Old Road Campus, Headington, OX3 7LF

To Join: This is a free event, which will be taking place both in-person and online via Zoom/Microsoft Teams. Register



While previous studies have reviewed how real-world data (RWD) have informed health technology assessment (HTA) across different settings and HTA bodies, they fail to provide a clear picture of the extent to which RWD is used specifically to inform the estimation of treatment effects. This is important for two reasons: 1) evidence on the relative effectiveness of treatments tends to be central to the decision as to whether the health technology is recommended for use, and 2) decision-makers are acutely aware of the various biases and pitfalls of RWD for deriving valid estimates of treatment effects, not least because most RWD are not collected for research purposes. We investigated how RWD has been explicitly used in estimating treatment effects on health outcomes or economic endpoints in NICE health technology appraisals. We pay particular attention to the RWD sources, the methods and analytical strategies used for deriving treatment effectiveness. We critique the limitations of current RWD usage and its potential impact on NICE reimbursement decisions.



Yoojung Che is a PhD student under the supervision of Manuel Gomes and Michail Katsoulis at the Department of Applied Health Research, University College London. She holds an MSc in Economics (Lund University), an MPhil in Environmental Policy (University of Cambridge), and a BA in Economics (Keio University). Her PhD is investigating the use of Real World Data in health economic evaluation.  

Forthcoming External Talks